Who could have bailed out Maria Sharapova in her lone struggle? Former superstar Chris Evert pointed out that she has no friends in the tennis circuit. But one “friend” can save Maria Sharapova, that’s Pharmacokinetics. Sharapova isolated herself from other players, but she shouldn’t be avoiding Pharmacokinetics.
Sharapova was tested positive by World Anti-Doping Agency for taking PED Meldonium at the Australian Open in January. The Russian queen herself provided the stuff to the WADA on January 26. Unfortunately for the Russian beauty, Meldonium was categorized as a banned substance by the International Tennis Federation from January 1, 2016.
Sold under the brand name Mildronate, the rationale is that Meldonium increases endurance, exercise tolerance and speed recovery by improving blood flow and impacting on the central nervous system, according to the Forbes.
The positive test result provisionally banned the former Wimbledon champion Sharapova, one of the highest-earning athletes of the planet from the professional tennis tour. The time period of this ban remains to be determined.
A one- or two-day hearing will commence in London on May 18. This provides the Russian beauty queen to plea for a lesser punishment. But a verdict will not be handed out until June. Now, what would be Sharapova’s argument, and what could help her to loosen the noose? Pharmacokinetics. But how?
Pharmacokinetics is sometimes described as what the body does to a drug, refers to the movement of the drug into, through, and out of the body—the time course of its absorption bioavailability and distribution. So this branch of pharmacology may prove that the PED had no impact on Sharapova’s body.
Sharapova, meanwhile remained upbeat expecting her return from the ban soon by posting pictures of her practice sessions in social media accounts.
Photo Courtesy: Matthew Stockman/Getty Images